# 177Lu rhPSMA‑10.1 Injection

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/177lu-rhpsma101-injection
Canonical HTML page: https://getbiobrief.com/entity/177lu-rhpsma101-injection

## Timeline

- **2026-07-09**: First Participant Dosed — Blue Earth Therapeutics and UCL announced initiation of the Phase 1 trial (NCT07414940) with first participant receiving Actinium (225Ac) rhPSMA-10.1 Injection.

## Recent coverage (1 stories)

### Phase 1 Trial Launches for Ac-225 PSMA Therapy: 1st Patient Dosed in mCRPC
2026-07-27 07:34:44 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Blue Earth Therapeutics doses first patient in Phase 1 trial of actinium-225 rhPSMA-10.1 for mCRPC, aiming to assess safety and inform dose selection. The trial leverages PSMA targeting with high-energy alpha particles to kill cancer cells. Results could shape the next wave of radioligand therapies.
Full story: https://getbiobrief.com/story/blue-earth-phase1-ac225-psma-trial-first-patient

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.